CL2021000585A1 - Métodos para tratar la pancreatitis - Google Patents

Métodos para tratar la pancreatitis

Info

Publication number
CL2021000585A1
CL2021000585A1 CL2021000585A CL2021000585A CL2021000585A1 CL 2021000585 A1 CL2021000585 A1 CL 2021000585A1 CL 2021000585 A CL2021000585 A CL 2021000585A CL 2021000585 A CL2021000585 A CL 2021000585A CL 2021000585 A1 CL2021000585 A1 CL 2021000585A1
Authority
CL
Chile
Prior art keywords
methods
pancreatitis
treat pancreatitis
subject
treat
Prior art date
Application number
CL2021000585A
Other languages
English (en)
Inventor
Dannielle D Engle
David A Tuveson
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of CL2021000585A1 publication Critical patent/CL2021000585A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se proporciona un método para prevenir, tratar, mejorar o controlar la pancreatitis en un sujeto que lo necesite, el cual comprende administrar al sujeto una cantidad terapéuticamente eficaz de un anticuerpo o fragmento funcional del mismo que se une a CA19-9.
CL2021000585A 2018-09-10 2021-03-09 Métodos para tratar la pancreatitis CL2021000585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10

Publications (1)

Publication Number Publication Date
CL2021000585A1 true CL2021000585A1 (es) 2021-08-13

Family

ID=69776851

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021000585A CL2021000585A1 (es) 2018-09-10 2021-03-09 Métodos para tratar la pancreatitis
CL2022000091A CL2022000091A1 (es) 2018-09-10 2022-01-13 Métodos para tratar la pancreatitis. (divisional de solicitud n° 202100585)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000091A CL2022000091A1 (es) 2018-09-10 2022-01-13 Métodos para tratar la pancreatitis. (divisional de solicitud n° 202100585)

Country Status (13)

Country Link
US (1) US20220049011A1 (es)
EP (1) EP3849605A4 (es)
JP (1) JP2022500382A (es)
KR (1) KR20210073515A (es)
CN (1) CN113056286A (es)
AU (1) AU2019337564A1 (es)
BR (1) BR112021004444A2 (es)
CA (1) CA3112382A1 (es)
CL (2) CL2021000585A1 (es)
IL (1) IL281343A (es)
MX (1) MX2021002761A (es)
SG (1) SG11202102416SA (es)
WO (1) WO2020055768A1 (es)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) * 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPS63159763A (ja) * 1986-12-24 1988-07-02 Fujirebio Inc 逆受身凝集反応試薬
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
NZ565937A (en) 2005-08-05 2011-09-30 Araim Pharmaceuticals Inc Tissue protective peptides and uses thereof
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
ES2539124T3 (es) 2008-01-22 2015-06-26 Araim Pharmaceuticals, Inc. Péptidos y análogos peptídicos protectores de tejido para la prevención y el tratamiento de enfermedades y trastornos asociados con daño tisular
JP5919604B2 (ja) * 2008-08-08 2016-05-18 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗膵癌抗体
MX2016000448A (es) 2013-07-17 2016-05-12 Araim Pharmaceuticals Inc Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
KR20160054501A (ko) * 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017189959A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease

Also Published As

Publication number Publication date
KR20210073515A (ko) 2021-06-18
SG11202102416SA (en) 2021-04-29
MX2021002761A (es) 2021-05-31
CA3112382A1 (en) 2020-03-19
US20220049011A1 (en) 2022-02-17
JP2022500382A (ja) 2022-01-04
CL2022000091A1 (es) 2022-11-18
EP3849605A1 (en) 2021-07-21
CN113056286A (zh) 2021-06-29
AU2019337564A1 (en) 2021-05-06
IL281343A (en) 2021-04-29
EP3849605A4 (en) 2022-06-15
WO2020055768A1 (en) 2020-03-19
BR112021004444A2 (pt) 2021-06-01

Similar Documents

Publication Publication Date Title
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CL2018002708A1 (es) Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
EA201990548A1 (ru) Лечение кластерной головной боли
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
MX2018009680A (es) Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3.
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
CO2021017688A2 (es) Anticuerpo biespecífico contra α-syn/igf1r y uso del mismo
CL2021000585A1 (es) Métodos para tratar la pancreatitis
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.